---
title: "雅培的 Esprit BTK 可溶解支架已獲加拿大衞生部批准"
description: "雅培已獲得加拿大衞生部批准其 Esprit BTK 依維莫司釋放可吸收支架系統，該可溶支架旨在治療膝下慢性肢體威脅缺血（CLTI）。該設備有助於保持動脈通暢，並釋放藥物依維莫司以促進癒合，直至其完全溶解，滿足超過 80 萬名患有外周動脈疾病（PAD）的加拿大人的需求"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/259344327.md"
published_at: "2025-09-29T12:37:47.000Z"
---

# 雅培的 Esprit BTK 可溶解支架已獲加拿大衞生部批准

> 雅培已獲得加拿大衞生部批准其 Esprit BTK 依維莫司釋放可吸收支架系統，該可溶支架旨在治療膝下慢性肢體威脅缺血（CLTI）。該設備有助於保持動脈通暢，並釋放藥物依維莫司以促進癒合，直至其完全溶解，滿足超過 80 萬名患有外周動脈疾病（PAD）的加拿大人的需求

雅培（Abbott Laboratories，股票代碼：ABT）週一宣佈，加拿大衞生部已批准其可溶解支架——Esprit BTK Everolimus Eluting Resorbable Scaffold System。

該設備用於治療下肢慢性威脅性缺血（CLTI）患者。它可以保持動脈通暢，並釋放藥物依維莫司，以支持在支架完全溶解之前的癒合。

超過 80 萬加拿大人患有周圍動脈疾病（PAD）。CLTI 是 PAD 的一種嚴重形式，動脈因斑塊堵塞而阻礙血液和氧氣流向小腿和腳部。CLTI 患者常常經歷劇烈疼痛和難以癒合的開放性傷口。

如需評論和反饋，請聯繫：editorial@rttnews.com

商業新聞

### Related Stocks

- [ABT.US - 雅培](https://longbridge.com/zh-HK/quote/ABT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Key facts: Exact Sciences to merge with Abbott by Q2 2026; 2025 revenue up 18% | Exact Sciences Corp. is merging with Abbott Laboratories, set to finalize in Q2 2026, pending approvals. The company als | [Link](https://longbridge.com/zh-HK/news/275986686.md) |
| Is the Market Bullish or Bearish on Abbott Laboratories? | Abbott Laboratories (NYSE:ABT) has seen a 14.02% decrease in short interest, with 15.88 million shares sold short, repre | [Link](https://longbridge.com/zh-HK/news/272305312.md) |
| SpaceX launches 12th long-duration crew to International Space Station | SpaceX successfully launched its 12th long-duration crew mission to the International Space Station (ISS) on February 13 | [Link](https://longbridge.com/zh-HK/news/275892766.md) |
| ISS A/S kauft insgesamt 15.326.483 Einheiten für 2.906.077.226 DKK im Rahmen des Rückkaufprogramms zurück | ISS A/S has repurchased units worth approximately 2.906 billion DKK as part of its ongoing buyback program. Following th | [Link](https://longbridge.com/zh-HK/news/275302046.md) |
| ASMPT Says Robin Gerard Ng Cher Tat To Retire From His Appointment As Group CEO | ASMPT Ltd :ROBIN GERARD NG CHER TAT TO RETIRE FROM HIS APPOINTMENT AS GROUP CHIEF EXECUTIVE OFFICER | [Link](https://longbridge.com/zh-HK/news/275386183.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。